KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Asset Writedowns and Impairment (2023)

Inovio Pharmaceuticals' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $2.0 million for Q2 2023.

  • For Q2 2023, Asset Writedowns and Impairment changed N/A year-over-year to $2.0 million; the TTM value through Dec 2024 reached $2.0 million, changed 0.0%, while the annual FY2023 figure was $2.0 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q2 2023 was $2.0 million at Inovio Pharmaceuticals.
  • Across five years, Asset Writedowns and Impairment topped out at $2.0 million in Q2 2023 and bottomed at $2.0 million in Q2 2023.